Exosome Payload Engineering via Optimized Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, such as antibody-drug conjugates, face limitations in payload capacity and specificity, leading to reduced potency and increased systemic toxicity due to limited targeting and high exposure to non-target tissues.
Innovation Solution
Extracellular vesicles, specifically exosomes, are engineered with biologically active molecules covalently linked via optimized linkers and anchoring moieties, allowing for higher payload density and targeted delivery by attaching molecules like antisense oligonucleotides using specific linkages and spacers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibody-drug conjugates are used to target specific cell types, then specificity is improved, but payload capacity is limited (typically 2-6 molecules per antibody)
Solution Approach 1:
The patent merges the targeting function (antibody) with the payload delivery function (drug molecules) by conjugating multiple drug molecules to a single antibody molecule through optimized linkers. This combining approach allows exceeding the typical 2-6 molecule limit by creating conjugates with higher drug-to-antibody ratios while maintaining targeting capability.
Solution Approach 2:
The patent employs composite material structures by creating antibody-drug conjugates with carefully designed linker compositions. The linkers are engineered as composite structures containing cleavable bonds, spacers, and stabilizing elements, allowing higher payload density while maintaining structural integrity and target-specific delivery.
2Reliability
If more biologically active molecules are attached to increase potency, then therapeutic efficacy is improved, but systemic toxicity increases due to exposure of non-target tissues
Solution Approach 1:
The patent changes the chemical parameters of the linker molecules to enable controlled drug release. By incorporating cleavable linkers with specific chemical bonds (e.g., disulfide bonds, peptide bonds) that are stable in circulation but cleaved in the target cell environment, the system achieves high payload capacity without proportional increase in systemic toxicity.
Solution Approach 2:
The patent introduces cleavable linkers as intermediary structures between the antibody and drug molecules. These linkers act as mediators that protect the drug during circulation (reducing systemic toxicity) while enabling drug release at the target site (maintaining therapeutic efficacy).
3Reliability
If cleavable linkers are used to enable controlled release, then therapeutic efficacy is improved, but linker stability during circulation may be compromised
Solution Approach 1:
The patent applies local quality by designing linkers with different stability characteristics at different locations and conditions. The linkers are engineered to be stable under circulation conditions (pH 7.4, physiological temperature) but become cleavable under specific local conditions at the target site (acidic pH, specific enzyme presence, reducing environment), achieving both stability and controlled release.
Data Source
AI summary
The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via an optimized linker and an anchoring moiety, which may be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.